KIadis naar de FDA

(AJK) KIadis staat nu 8,8% hoger op dit nieuws, onderzoek bij de FDA:

• 09 Apr - 08:30:00 [RTRS] - REG-KIADIS PHARMA FILES FIRST INVESTIGATIONAL NEW DRUG APPLICATION WITH THE U.S. FDA FOR NATURAL KILLER (NK) CELL THERAPY PRODUCED WITH PM21
• 09 Apr - 08:33:26 [RTRS] - KIADIS PHARMA NV - PLANS TO INITIATE A PHASE 1/2 STUDY WITH LEADING TRANSPLANT CENTERS IN THE U.S. TO EVALUATE K-NK002 ONCE IT RECEIVES FDA APPROVAL FOR THE IND
• 09 Apr - 08:34:36 [RTRS] - KIADIS PHARMA NV - ONCE APPROVED, WE ARE READY TO IMMEDIATELY INITIATE TRIAL WITH BMT CTN, AND RAMP UP PRODUCTION OF CLINICAL MATERIALS - CEO
• 09 Apr - 08:36:30 [RTRS] - KIADIS PHARMA NV - NK-REALM STUDY WILL ENROLL 63 PATIENTS AT LEADING TRANSPLANT CENTERS IN U.S

En dat kan de koers ook wel even gebruiken, zeg. Die smacht naar goed productnieuws.